John Mellors
Head of Cell and Antibody Therapy Discovery
We focus on paradigm-shifting science and biological capabilities such as multi-targeting CAR-Ts, antibodies and fully-human antibody engineering.
Innovation areas
We aim to address patient needs through transformational innovation. We bring together the best science, technology and next-generation biological capabilities from inside and outside our company.
Learn more about our approach in cell therapy, small molecules and biologicals.
Driving pipeline growth and leveraging cross-modality synergies
Differentiated Technology Platforms
Small Molecules
– Excellence, speed, agility: fully-integrated, end-to-end in-house capabilities
– Best-in-class strategy: validated targets to develop differentiated medicines
– 25 years of experience: enhanced by external partnerships
Cell Therapy
– Scalable, decentralized, fast: fresh, fit, stem-like, early memory cells within a median vein-to-vein time of seven days
– High-yielding discovery engine: multi-targeting, next-generation cell therapies
– Diversify and grow: through partnerships and M&A
Pipeline
Diversifying and accelerating our pipeline
We focus on delivering best-in-class medicines with transformational impact for patients by accelerating life-changing science and innovation in the fields of immunology and oncology.
Disease areas
Pioneering for patients
We know that patients in need are waiting. That is why we focus on therapeutic areas where we aim to make transformational impact happen faster, including oncology and immunology.
Our stories
More about our company, science and people
We curate a series of inspiring stories about how we are #LivingInnovation at Galapagos
Partnerships
Work with us!
We are adding new capabilities, technologies and product candidates through internal and external innovation. Let’s start #PioneeringForPatients, together!